Epcoritamab as a follow-up treatment for CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CLL or SLL that was diagnosed using standard 2018 criteria.
- You have been treated with acalabrutinib or zanubrutinib (with or without obinutuzumab) for at least 12 months as your first therapy.
- Your disease decreased by at least half but is still detectable in blood or bone marrow by a highly sensitive test called ClonoSEQ.
- You are at least 18 years old.
- You are physically active and able to care for yourself (ECOG 0-2).
- You must not be pregnant and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an investigational drug called epcoritamab, given after your usual treatment (a BTK inhibitor), to see if it can clear remaining CLL cells and reduce the chance of the cancer coming back. It's for people with CLL that has high-risk features, like genetic changes or resistance to prior treatments.
This trial tests two drugs, pirtobrutinib and epcoritamab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after at least one previous treatment. The goal is to see if this combination can help control the disease.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This early-phase study tests whether combining venetoclax (a tablet) with epcoritamab (a targeted antibody) can control CLL/SLL that has come back or did not respond. It may help by boosting the immune system’s ability to attack the cancer while keeping the treatment schedule in cycles.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.